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Cullin-RINGE3 ubiquitin ligases (CRLs) are large and diverse
multisubunit protein complexes that contribute to about one-
fifth of ubiquitin-dependent protein turnover in cells. CRLs are
activated by the attachment of the ubiquitin-like protein neural
precursor cell expressed, developmentally down-regulated 8
(NEDD8) to the cullin subunits. This cullin neddylation is essen-
tial for a plethora ofCRL-regulated cellular processes and is vital
for life. In mammals, neddylation is promoted by the five co-E3
ligases, defective in cullin neddylation 1 domain-containing 1–5
(DCNL1–5); however, their functional regulation within the
CRL complex remains elusive. We found here that the ubiqui-
tin-associated (UBA) domain–containingDCNL1 ismonoubiq-
uitylatedwhenbound toCRLs and that thismonoubiquitylation
depends on the CRL-associated Ariadne RBR ligases TRIAD1
(ARIH2) andHHARI (ARIH1) and strictly requires theDCNL1’s
UBA domain. Reconstitution of DCNL1 monoubiquitylation in
vitro revealed that autoubiquitylated TRIAD1mediates binding
to the UBA domain and subsequently promotes a single ubiqui-
tin attachment to DCNL1 in a mechanism previously dubbed
coupled monoubiquitylation. Moreover, we provide evidence
that DCNL1 monoubiquitylation is required for efficient CRL
activity, most likely by remodeling CRLs and their substrate
receptors. Collectively, this work identifies DCNL1 as a critical
target of Ariadne RBR ligases and coupled monoubiquitylation
of DCNL1 as an integrated mechanism that affects CRL activity
and client–substrate ubiquitylation at multiple levels.
Cullin-RING E3 ubiquitin ligases (CRLs)2 are a large and
diverse family of multisubunit protein complexes responsible
for as much as 20% of ubiquitin-dependent protein turnover in
cells (1–3). Their complexity lieswithin their commonmodular
composition, comprising a central elongated cullin protein
scaffold that binds a RING E3 ubiquitin ligase (RBX1 or RBX2)
and one out of 200 different substrate receptor complexes.
The activity of CRLs is tightly controlled by the dynamic
remodeling of CRL architecture, through reversible cullin ned-
dylation and CAND1-promoted substrate receptor exchange.
CRL neddylation, the ligation of the ubiquitin-like protein
NEDD8 to a single conserved lysine on the cullin subunit, is
central to a conformational switch within the C-terminal
RING–binding domain of the cullin, to promote ubiquitin
transfer to substrates (1, 4–6). Like other ubiquitin-like (UBL)
proteins, NEDD8 conjugation to the substrate lysine utilizes a
cascade of E1-activating, E2-conjugating, and E3-ligating
enzymes (7, 8). Unique to cullin neddylation is the use of an
N-terminal acetylated NEDD8 E2 (UBE2M/UBC12 or UBE2F
in the CUL5 neddylation (9, 10)), which in turn is critical for a
“dual E3” mechanism (5). First, the RING E3 RBX1 (or RBX2 in
CUL5 neddylation) acts as a conventional RING ligase by
binding to the cullin substrate and subsequently activating the
thioester-linked UBC12NEDD8 intermediate to promote
NEDD8 ligation. Second, the “co-E3” DCNL1 (DCN1 in yeast)
binds the cullin and the N-terminally acetylated UBC12
NEDD8, thereby restricting the otherwise flexible RBX1–
UBC12NEDD8 in a conformation that orients UBC12’s cata-
lytic site toward the cullin acceptor lysine (5).
Although lower eukaryotes such as budding yeast have only
one DCN1 co-E3 (11), humans have five distinct DCN1-like
proteins named DCNL1–DCNL5 (10). Of these, DCNL1 most
closely resembles yeast DCN1 and is perhaps the best-studied
of the human proteins. Like its yeast counterpart, the human
DCNL1 contains an N-terminal ubiquitin-associated (UBA)
domain and a C-terminal potentiating neddylation (PONY)
domain that interacts with cullins via an acidic “DAD” surface
patch and is sufficient for cullin neddylation (5, 9, 12, 13). It is
currently not clear to what degree DCNL1 has selectivity
toward neddylating certain CRL complexes. Comprehensive
biochemical and cellular analyses revealed that DCNL1 is capa-
ble of binding all types of cullins in vitro and in vivo, albeit with
varying affinities (10, 14). Expression of DCNL1 enhanced cul-
lin-1 (CUL1) and CUL3 neddylation and was shown to be crit-
ical for CUL1 neddylation in the nucleus that promoted the
recruitment and nuclear translocation of neddylation compo-
nents (15). In addition, in a separate study, ectopically ex-
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pressedDCNL1wasmonoubiquitylated, and it was further sug-
gested that this monoubiquitylation drives DCNL1 nuclear
export (16).
Cullin neddylation is reversed by the eight-subunit COP9
signalosome (CSN), the sole-known isopeptidase to specifically
deconjugate NEDD8 from cullins (17). The substrate-free CSN
enzyme complex is autoinhibited; however, a recent protein
structural analysis revealed that CSN binding to the neddylated
CRL activates its hydrolysis activity (18). Notably, CSN also
exhibits a high affinity for the deconjugated cullin product and
maintains the CRL in an inactive state.
Increasing evidence has emerged that alternative regulatory
mechanisms exist and are coupled to neddylation/deneddyla-
tion. Data from elegant biochemical and cellular studies indi-
cate that the CAND1 protein promotes substrate–receptor
(SR) module exchange that depends on the neddylation state of
the cognate cullin (19–25). Although SRs are tightly associated
with cullin scaffolds, the presence of CAND1 can increase the
rate of SR dissociation by several orders of magnitude, allowing
the exchange of different SRs (19). This effect was abrogated
when the cullin complexwas neddylated, which is in agreement
with NEDD8’s ability to prevent CAND1 binding to cullins. In
contrast, NEDD8 also has the ability to promote binding of
CRL-associated proteins, such as UBXN7/p97 andmembers of
theAriadne Ring–Between–Ring (RBR) E3 ligases (26–28).We
have previously reported that the Ariadne RBRs, HHARI and
TRIAD1 (also known as ARIH1 and ARIH2, respectively),
interactwith distinct neddylatedCRLs, and this interaction acts
to stimulate Ariadne E3 ligase activity by relieving an autoin-
hibitory effect mediated by the “Ariadne” domain (28, 29).
Once activated, HHARI cooperates with cullin–RBX1 activity
for CRL client substrate ubiquitylation (30). In particular,
HHARI efficiently primes selected substrates with monoubiq-
uitin to promote subsequent polyubiquitylation by cullin–
RBX1 ligase activity. It remains to be mechanistically dissected
howHHARI and TRIAD1 integrate into the dynamic remodel-
ing of the CRL–SR complex by CAND1 and the CRL neddyla-
tion/deneddylation cycle controlled by the DCNL1 family and
CSN.
Here, we identified a novel, functional link between Ariadne
RBRs and DCNL1. We show that the Ariadne E3 ubiquitin
ligase activities of TRIAD1 and HHARI are required for effi-
cient monoubiquitylation of DCNL1 both in vitro and in
vivo. We have determined the mechanism by which TRIAD1
promotes ubiquitylation of DCNL1 as coupled monoubiqui-
tylation. Our findings collectively suggest that DCNL1
monoubiquitylation is required for efficient CRL activity,
most likely by promoting remodeling of CRLs and their sub-
strate receptors.
Results
TRIAD1 and HHARI are required for cellular DCNL1
monoubiquitylation
To investigate the impact of TRIAD1/NEDD8–CUL5 bind-
ing on the overall CUL5 ligase complex assembly and neddyla-
tion cycle, we analyzed the association of the NEDD8 conjuga-
tion/deconjugation machinery, DCNL1 and CSN. Endogenous
CUL5 complexes were first immunoprecipitated from cells
stably expressing GFP–TRIAD1 or inactive E3 ligase GFP–
TRIAD1 (C310S), and co-precipitated proteins were then
determined by immunoblot analyses. GFP–TRIAD1 (C310S)-
expressing cells showed reduced levels of CUL5-associated
CSN subunits CSN5 and CSN8 (Fig. 1A, lanes 8 and 9), and
DCNL1 (Fig. 1B, lanes 5 and 6). We further noted that
the slower-migrating form of monoubiquitylated DCNL1
(DCNL1-Ub) was markedly reduced in the GFP–TRIAD1
(C310S) cell lysate (Fig. 1B, input). To our knowledge, endoge-
nous DCNL1-Ub has not been detected previously. Endoge-
nousDCNL1-Ub is enriched in the cytosol, as was described for
ectopically expressed DCNL1 (Fig. 1C) (31). We further
assessed whether DCNL1 is indeed conjugated with ubiquitin
rather than with NEDD8. We treated HA immunoprecipitates
of cells expressing HA–DCNL1 with either the pan-ubiquitin–
deconjugating enzyme USP2 or the deneddylating enzyme
NEDP1 (32). USP2 but not NEDP1 efficiently deconjugated
DCNL1, confirming monoubiquitin-modified DCNL1 (Fig.
1D). We next asked whether the ligase activity of HHARI, the
Ariadne subfamily member most closely related to TRIAD1, is
also required for DCNL1-Ub. We analyzed the abundance of
endogenous DCNL1-Ub in cytosolic fractions of cells express-
ing catalytically inactive Ariadne variants (TRIAD1 (C310S)
and HHARI (C357S)), constitutive ligase-active variants con-
tainingmutations that relieve autoinhibition (TRIAD1 (R371A,
E382A, and E455A) and HHARI (F430A, E431A, and E503A))
(28, 29), and a combination of these mutations. Catalytically
dead variants of both Ariadne RBRs (Fig. 1, E and F, lanes 2 and
4) reduced the abundance of DCNL1-Ub in the cytosol,
whereas autoinhibition-relieved variants had no significant
impact (Fig. 1, E and F, lane 3). Taken together, these data
indicate that the E3 ubiquitin ligase activities of TRIAD1 and
HHARI are required for efficient DCNL1 monoubiquitylation
in cells.
DCNL1 ismonoubiquitylated by TRIAD1 and HHARI in vitro
We next tested whether TRIAD1 can directly target DCNL1
for ubiquitylation in an in vitro assaywith purified recombinant
proteins. In a complete ubiquitylation reaction containing the
ubiquitin-activating E1 enzyme UBE1, the cognate E2-conju-
gating enzyme for Ariadne RBRs UBCH7 (33, 34), DCNL1 as
substrate, and neddylated CUL5–RBX2 (N8–CUL5–RBX2),
TRIAD1 efficiently monoubiquitylated DCNL1 (Fig. 2A). Con-
sistent with our previous finding in substrate-free assays
(28), the presence of N8–CUL5–RBX2 stimulates TRIAD1
ligase activity and DCNL1-Ub conjugation. To further assess
N8–CUL5–RBX2 stimulation of TRIAD1 in the context of a
substrate, we set up a quantitative ubiquitylation assay with
fluorescein-labeled ubiquitin (Ub5-IAF). Monitoring the for-
mation of DCNL1-Ub5-IAF with 100 nM TRIAD1 in the pres-
ence of 100 nM N8–CUL5–RBX2 revealed a robust enhance-
ment of TRIAD1 substrate conjugation activity (Fig. 2, B and
C). Importantly, DCNL1 monoubiquitylation is strictly de-
pendent on catalytically active TRIAD1. Replacing WT
MBP-tagged TRIAD1 (MBP–TRIAD1) with catalytic inac-
tive MBP–TRIAD1 (C310A) completely abolished DCNL1-
Ub despite the presence of N8–CUL5–RBX2 (Fig. 2D). We
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next tested whether HHARI can also directly target DCNL1
for monoubiquitylation. We used a truncation of HHARI
that lacked the autoinhibitory Ariadne domain HHARI
(ARI). This HHARI (ARI) variant is fully active, even
in the absence of neddylated CUL1–RBX1 (28, 29). In a
complete ubiquitylation reaction with either UBCH7 or
UBCH5c, we observed a robust monoubiquitylation of
DCNL1 by HHARI (ARI) (Fig. 2E). In summary, both
TRIAD1 and HHARI are capable of directly monoubiquity-
lating DCNL1 in vitro.
UBA domain of DCNL1mediates binding to autoubiquitylated
TRIAD1
We next aimed to examine the mechanism of DCNL1
monoubiquitylation by TRIAD1 and initially investigated how
TRIAD1 might bind the DCNL1 substrate. Ubiquitin-binding
domain (UBD)–containing proteins, including UBA domain–
containing proteins, are commonly ubiquitylated by a process
that depends on a functional UBDdomain (35, 36).We hypoth-
esized that DCNL1’s UBAmediates binding to TRIAD1, a pre-
requisite to be targeted for ubiquitylation. However, there are
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conflicting data regarding whether UBA binds monomeric
ubiquitin molecules and/or ubiquitin chains (11, 31). To
address this issue, recombinant purified DCNL1, UBA-deleted
DCNL1 (PONY), and the isolated UBA domain were used to
test their binding capabilities to monomeric ubiquitin or
NEDD8 that were coupled to an agarose-basedmatrix. DCNL1,
as well as the isolated UBA domain, had a preference for ubiq-
uitin over NEDD8 (Fig. 3A). Notably, DCNL1missing the UBA
domain failed to bind ubiquitin. Next, we tested DCNL1 bind-
ing to a set of ubiquitin tetramers of seven different linkage
DCNL1
TRIAD1
N8-CUL5
UBE1
UBCH7
co
m
pl
et
e
–
D
CN
L1
–
N
8-
CU
L5
-R
BX
2
–
TR
IA
D
1
20
30
50
100
kDa
80
25
MBP-TRIAD1:
50
40
30
100
kDa
80
50
40
30
2015
IB
: D
CN
L1
IB
: U
bi
qu
itin
N8-CUL5–RBX2:
wt wt wt C31
0A
(U
b)
n
BA
DCNL1-UbIB
: U
bi
qu
itin
30
50
100
kDa
80
30
DCNL1-Ub
40
40
20
30
50
100
kDa
80
25
IB
: D
CN
L1
Co
om
as
sie
 s
ta
in
DCNL1
DCNL1-Ub
Co
om
as
sie
 s
ta
in
DCNL1:
UBCH7:
+ + + +
+ – + +
– + + +
D
5-
IA
F 
si
gn
al
 in
te
ns
ity
 (a
rbi
tra
ry 
un
its
)
0
5
10
15
20
25
30
35
0 50 100 150
time (min)
100 nM TRIAD1
+ N8-CUL5-RBX2
100 nM TRIAD1
D
CN
L1
-U
b5
’-I
AF100
kDa
220
50
40
100nM TRIAD
100nM TRIAD
N8-CUL5–RBX2
nim0210603020150
C
0 5 10 20 30 60120
TR
IA
D
1-
(U
b5’
-IA
F ) n
DCNL1
UBCH7
DCNL1-Ub
DCNL1-Ub
DCNL1
DCNL1-Ub
20
30
60
100
kDa
80
25
IB
: H
A 
(U
biq
uit
in)
30
40
IB
: D
CN
L1
Co
om
as
sie
 s
ta
in
DCNL1
HHARIARI
DCNL1-Ub
co
m
pl
et
e
–
D
CN
L1
–
H
H
AR
IA
R
I
–
E2 co
m
pl
et
e
–
D
CN
L1
–
H
H
AR
IA
R
I
–
E2
UBCH7 UBCH5c
50
40
DCNL1
DCNL1-Ub
Ub
H
A -
co
n
jug
ate
s
DCNL1-Ub
20
30
60
100
kDa
80
25
50
40
Ub
H
A -
co
n
jug
ate
s
Ub
H
A -
co
n
jug
ate
s
E
Figure 2. TRIAD1 and HHARI monoubiquitylate DCNL1 in vitro. A, reconstitution of DCNL1 monoubiquitylation with purified recombinant TRIAD1, ned-
dylatedCUL5–RBX2 (N8–CUL5–RBX2), andUBCH7. Products of complete anddrop-out () reactionswere separatedonSDS-PAGEanddetectedbyCoomassie
stain as well as immunoblot analysis as indicated. B, quantitative ubiquitylation assay with fluorescein-labeled ubiquitin (Ub5-IAF) in the absence or presence
of N8–CUL5–RBX2. Samples were taken at indicated time points and resolved on SDS-PAGE and scanned at 520 nm to visualize reaction products. C,
quantitation of DCNL1-Ub signal from B using ImageJ software. Standard error of the mean is given from two independent replicates. D, DCNL1 monoubiq-
uitylation with purified recombinant WT MBP–TRIAD1 or catalytically dead mutant MBP–TRIAD1 (C310A) with drop-out () UBCH7 and DCNL1 controls.
Reaction products were separated on SDS-PAGE and detected by Coomassie stain as well as immunoblot analysis as indicated. E,DCNL1monoubiquitylation
reactions with HHARI that lacks the autoinhibitory Ariadne domain HHARI (ARI) using UBCH7 or UBCH5c as E2 enzymes including drop-out () E2, E3, and
DCNL1 controls. Reaction products were separated on SDS-PAGE and detected by Coomassie stain and immunoblot analysis as indicated.
DCNL1monoubiquitylation by Ariadne E3 ligases
2654 J. Biol. Chem. (2019) 294(8) 2651–2664
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
arch 13, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
types (Met-1 or linear, Lys-6, Lys-11, Lys-29, Lys-33, Lys-48,
and Lys-63) that can currently be engineered in vitro (37).
ImmobilizedHalo-taggedDCNL1 efficiently interactedwith all
tested ubiquitin tetramers regardless of their linkage type.
However, DCNL1 with a mutated UBA (F15A, M16A, F44A,
and F45A) domain (DCNL1MUT), which was previously shown
to be defective in ubiquitin binding (31), failed to interact, sug-
gesting that DCNL1 association with ubiquitin tetramers is
strictly dependent on the presence of a functional UBA domain
(Fig. 3B). We therefore conclude that human DCNL1 can bind
both monoubiquitin and polyubiquitin chains.
We showed recently that once activated, both TRIAD1 and
HHARI are efficient in autoubiquitylation, particularly in the
absence of a substrate. In agreement with ubiquitin ligation, we
noted a higher molecular weight species of TRIAD1 by immu-
noblot analysis of whole-cell lysates. This species was absent
when catalytically inactive TRIAD1 was expressed, indicating
that a subfraction of TRIAD1 is autoubiquitylated in cells. To
further test that TRIAD1 was ubiquitylated, we immunopre-
cipitated GFP–TRIAD1 and treated the precipitate with the
pan-deubiquitylase USP2. Indeed, USP2 but not heat-inacti-
vated USP2 depleted the slowermigrating, and hence ubiquity-
lated, form of TRIAD1 (Fig. 3E). Similar results were obtained
for HHARI, showing that HHARI is autoubiquitylated to a sig-
nificant degree in cells (Fig. 3F). Treatment of cells with the
proteasomal inhibitor MG132 prior to cell lysis did not signifi-
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Figure 3. Autoubiquitylated TRIAD1 associates with the UBA domain of DCNL1. A, in vitro binding assay to assess binding between DCNL1, UBA-deleted
DCNL1 (PONY), and isolated UBA domain and either ubiquitin (Ub)- or NEDD8-agarose beads. Samples of input and beads-bound (Pellet) fraction were
analyzed by individual anti-DCNL1 immunoblots. TRIAD1 with NEDD8-binding preference was used as comparison. B, Halo-tagged DCNL1 and mutated
DCNL1 comprising a Ub-binding–deficient UBA domain (input visualized by Coomassie-stained SDS-PAGE), were incubatedwith ubiquitin tetramers (Ub4) of
seven different linkage types. Bound fractions of ubiquitin tetramers were detected and shown by silver-stained SDS-PAGE. C and D, cell lysates of mock- or
MG132-treatedHEK293cells expressing the indicatedGFP-taggedvariantsof TRIAD1orHHARIwereanalyzedbyanti-GFP immunoblot analysis.-Actin served
as loadingcontrol. Eand F,GFPprecipitatesofHEK293cells expressingGFP–TRIAD1,GFP-HHARI, or their catalyticCys toSermutant variantsweremock-treated
and incubatedwith USP2 or heat-inactivated USP2, followed by anti-TRIAD1 (E) and anti-HHARI (F) immunoblot analysis.G, in vitroMBP-pulldown experiment
with mock or autoubiquitylated MBP–TRIAD1 and DCNL1, DCNL1 (PONY), and DAD patch-mutated (DADmut) DCNL1. DCNL1 input was monitored by Coo-
massie-stained SDS-PAGE, and MBP-pellet samples were analyzed by immunoblot.
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cantly enrich for TRIAD1 and HHARI protein levels (Fig. 3, C
and D), suggesting that ubiquitin ligation might facilitate a
functional role other than a target for proteasomal degradation.
We next tested whether autoubiquitylation of TRIAD1 pro-
motes efficient binding to DCNL1. In vitro pulldown assays
were carried out with mock-treated and autoubiquitylated
MBP–TRIAD1 in the presence of DCNL1, DCNL1 (PONY)
(comprising amino acids 59–259), and DAD-patch mutated
DCNL1 (DADMUT) (containing D211A, A235R, D241A amino
acid replacements). We observed that DCNL1 but not DCNL1
(PONY) specifically co-precipitated with ubiquitylated MBP–
TRIAD1 (compare lane 3 with 5), indicating that TRIAD1
autoubiquitylation was critical for mediating binding to the
UBAdomain of DCNL1 (Fig. 3G). Notably, the DAD-patchwas
dispensable for TRIAD1/DCNL1 interaction (Fig. 3G, lane 7).
TRIAD1 targets DCNL1 by coupledmonoubiquitylation
Having established the molecular determents of the interac-
tion between TRIAD1 and DCNL1, we next asked whether this
interaction is required to support ubiquitin ligation to DCNL1
(Fig. 4A). Our model predicted that DCNL1 monoubiquityla-
tion depends on the UBA domain. Analysis of lysates from cells
expressing HA–DCNL1 and HA–DCNL1 (DADMUT) showed
significant DCNL1 monoubiquitylation, to levels similar to
those observed for endogenous DCNL1. However, no monou-
biquitylated form of the truncated HA–DCNL1 (PONY) was
detected in lysates (Fig. 4B, INPUT) nor inHA-immunoprecipi-
tates (Fig. 4B, IP:HA), indicating that the UBA domain was
required for substrate recognition. In agreement, recombinant
DCNL1 (PONY) was not efficiently monoubiquitylated by
N8–CUL5–RBX2-activated TRIAD1 in vitro (Fig. 4C). To fur-
ther test the importance of the ubiquitin/UBA interaction for
substrate recognition, we compared in our ubiquitylation reac-
tionWT ubiquitin with a ubiquitin mutant of the hydrophobic
patch (I44A) that cannot bind UBA domains. Analysis of
DCNL1 monoubiquitylation showed that replacing ubiquitin
with I44A ubiquitin clearly abolished DCNL1monoubiquityla-
tion in vitro (compare lane 5 and 6), demonstrating that the
Ile-patch was required in the process of DCNL1 ubiquitylation
(Fig. 4D). Notably, TRIAD1 autoubiquitylation and hence
TRIAD1 ligase activity was not affected by I44A ubiquitin. To
further dissect the mechanism of DCNL1 monoubiquitylation,
we addressed the role of the E2-conjugation enzyme. Studies by
Hoeller et al. (38) demonstrated that several UBA-containing
proteins could be directly monoubiquitylated by E2-conjugat-
ing enzymes in vitro and bypass E3 ubiquitin ligase activity. To
test whether this mechanism applied for DCNL1, we set up
DCNL1 ubiquitylation reactions in the absence of TRIAD1 but
with either UBCH5c or UBCH7 as E2 enzymes. UBCH5c effi-
ciently formed ubiquitin chains as well as ubiquitin-conjugated
DCNL1 (Fig. 4E). Instead, the cognate UBCH7, which was used
in all our standard reactions with TRIAD1, was incapable of
directly targeting DCNL1 (Fig. 4E) underpinning a critical role
of TRIAD1 in ubiquitin ligation onto DCNL1 (Fig. 4D).
Our working model proposes that autoubiquitylation of
TRIAD1 promotes substrate interaction via DCNL1’s UBA
domain (Fig. 4A, red arrow). To determine the requirement of
TRIAD1 autoubiquitylation in the process of DCNL1 monou-
biquitylation, the ubiquitylation reaction was divided in two
steps. In the first step, TRIAD1 was pretreated with WT ubiq-
uitin for 30 min in an autoubiquitylation reaction. In parallel, a
mock TRIAD1 autoubiquitylation reaction was carried out (no
autoubiquitylation). Subsequently, DCNL1 was added in the
second step, and the ubiquitylation reactionwas resumed for 30
min to monitor DCNL1 monoubiquitylation. Autoubiquity-
lated TRIAD1 significantly enhancedDCNL1monoubiquityla-
tion compared with mock-treated TRIAD1 suggesting that
TRIAD1 autoubiquitylation is a prerequisite to promote ubiq-
uitin ligation to DCNL1 (Fig. 4F). Next, we tested whether the
enhancedDCNL1monoubiquitylation ismediated by the ubiqui-
tin/UBA interaction, as already suggested in Fig. 4D. Using a sim-
ilar two-step assay approach, TRIAD1 autoubiquitylation was
either carried out withWT ubiquitin or I44A-mutated ubiquitin,
and the reactionwas resumed in thepresenceofDCNL1. In agree-
mentwith ourmodel, TRIAD1 autoubiquitylatedwith I44Aubiq-
uitin failed to enhance DCNL1 monoubiquitylation, due to dis-
rupted interaction between autoubiquitylated TRIAD1 and the
UBA domain of DCNL1 (Fig. 4G). Importantly, TRIAD1 autou-
biquitylationwith I44Awas indistinguishable fromWTubiquitin.
In conclusion,monoubiquitylation of DCNL1 byTRIAD1 utilizes
a mechanism mediated by an interaction between autoubiquity-
lated TRIAD1 and the DCNL1 UBA domain. A similar mecha-
nism has been described for the monoubiquitylation of other
UBA-containing proteins, including Sts2 and Eps15, and was
termed “coupledmonoubiquitylation” (35, 36).
Monoubiquitylation does not alter DCNL1 co-E3 ligase activity
for cullin neddylation in vitro
The functional and physiological role of coupled monoubiq-
uitylation is not defined for the majority of UBD-containing
substrates. Amechanism of intramolecular regulation was pro-
posed for UBD-substrates whereby the monoubiquitin moiety
interacts with the UBD in “cis” and consequently prevents any
interaction with other ubiquitylated proteins in “trans.” Alter-
natively, the cis interaction induces changes in the structure
and/or the functional activity of the protein (39). We set out to
test the latter possibility regarding whether monoubiquityla-
tion impacts co-E3 ligase activity of DCNL1 using in vitro cullin
neddylation assays. In neddylation assays with recombinant
NEDD8 E1-activating enzyme (APPBP1/UBA3), N-terminally
acetylated UBE2F as E2, and NEDD8, CUL5–RBX2 was mod-
estly neddylated but significantly enhanced in the presence of
DCNL1 or DCNL1 (PONY) as described previously (Fig. 5, A
and B) (5, 10, 12). Notably, DCNL1 (DADMUT), which cannot
bind cullins, was not capable of stimulating CUL5 neddylation.
Wenext affinity-purifiedmonoubiquitylatedDCNL1 (DCNL1-
UbHA) from up-scaled in vitro ubiquitylation reactions (see
“Experimental procedures” for details) (Fig. S1). Alternatively,
to mimic a monoubiquitylated form of DCNL1, we expressed
and purified recombinant DCNL1 with a C-terminal fusion of
monoubiquitin (DCNL1-UbCT). The addition of DCNL1-
UbHA or DCNL1-UbCT enhanced CUL5 neddylation to the
same levels as DCNL1, arguing against a functional role of
monoubiquitin in regulating the co-E3 neddylase activity of
DCNL1 (Fig. 5, C and D).
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DCNL1monoubiquitylation influences Cullin RING ligase
complex remodeling and activity
The in vitro experiments using the minimal CUL5–RBX2
complex as substrate indicated that neither the UBA domain
nor monoubiquitylation affected the co-E3 neddylase activity
of DCNL1. To investigate DCNL1 monoubiquitylation in the
context of cellular CRL complexes, we generated cell lines sta-
bly expressing HA-tagged DCNL1, DCNL1 (PONY), and
DCNL1-UbCT (C-terminal ubiquitin fusion). In agreement
with published work (14), all tested cullins (CUL1, -2, -3, -4A,
-4B, and -5) co-immunoprecipitated with DCNL; however, we
noted that DCNL1 (PONY) and DCNL1-UbCT had a higher
preference for associatingwith the non-neddylated formof cul-
lins (Fig. 6A). We next asked whether monoubiquitylation of
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DCNL1 changes the steady-state composition of CRL com-
plexes with their associated regulatory components CSN and
CAND1. HA–DCNL1 and variants were immunoprecipitated
and analyzed by immunoblot analysis. CRL complexes associ-
ated with DCNL1 (PONY) or DCNL1-UbCT displayed a lower
abundance of CSN components such as CSN3, CSN7B, and
CSN8 (Fig. 6B), but they had unexpectedly increased levels of
CAND1 (Fig. 6C). DCNL1 and CAND1 are apparently not
mutually exclusive in binding to CRLs, supporting previous
observations (14). In agreement with increased CAND1 bind-
ing, we observed reduced binding of the CUL2 and CUL5 sub-
strate receptor/adaptor Elongin-C. These results indicated a
potential role ofDCNL1monoubiquitylation in cullin substrate
receptor/adaptor engagement. Indeed, recent work described a
function for DCNL1 as substrate sensor and activator of
CUL2–ElonginB/C–VHL complexes and ubiquitylation-medi-
ated proteasomal degradation of Hif1 (40). Hence, we next
focused our studies on CUL2-regulated turnover of Hif1. The
protein level of Hif1was assessed in lysates from cells overex-
pressing HA–DCNL1 and HA–DCNL1-UbCT that were either
mock-treated or exposed to the proteasomal inhibitor MG132
or the NEDD8 E1–activating enzyme inhibitor MLN4924. As
expected, under normoxic conditions Hif1 was rapidly
degraded, but accumulated in the presence ofMG132, aswell as
MLN4924, due to the inhibition of the ubiquitin proteasome
system and the cullin ligase, respectively (Fig. 6,D and E). Hif1
was further enriched in MG132-treated HA–DCNL1-UbCT-
expressing cells (Fig. 6, D and E, lanes 4 and 6) suggesting that
the monoubiquitylated form of DCNL1 impeded cullin ligase
activity. However, when CRL activities were blocked by
MLN4924, HA–DCNL1 and HA–DCNL1-UbCT cells showed
the same level of Hif1 accumulation (Fig. 6D). We chose
another well-studied CRL/substrate system, the IB degrada-
tion in NF-B signaling, to further test the effects of
HA–DCNL1-UbCT. HA–DCNL1 and HA–DCNL1-UbCT-ex-
pressing cells were stimulated with TNF, and IB degrada-
tion as well as NF-B activation by phospho-p65 was
assessed by immunoblotting. HA–DCNL1-UbCT-expressing
cells showed a modest defect in IB degradation, and this
defect resulted in a delay in p65 phosphorylation (P-p65)
(Fig. 6, F andG). Cumulatively, the data suggest that monou-
biquitylation of DCNL1 has, at least for some CRLs, a regu-
latory function in substrate receptor/adaptor engagement
and substrate targeting.
Discussion
Assembly and activity of CRLs are kept in a highly dynamic
state to generate CRL complexes on demand for efficient and
selective client substrate ubiquitylation (41, 42). This is driven
by cullin neddylation/deneddylation on the one hand and
CAND1 substrate receptor exchange on the other hand; how-
ever, the intricate interplay of these processes is less well under-
stood. Here, we provide detailed mechanistic insight showing
that the NEDD8 co-E3 ligase DCNL1 is regulated by coupled
Figure4.DCNL1monoubiquitylationdependsonUBAdomainand is stimulatedbyautoubiquitylatedTRIAD1.A,workingmodelproposing thatDCNL1
monoubiquitylation is promoted by an interaction between DCNL1’s UBA and autoubiquitylated TRIAD1. B, HA immunoprecipitates of HEK293 cells stably
expressing HA-tagged DCNL1 (WT), DCNL1 (DADMUT), or DCNL1 (PONY) were analyzed by immunoblot analysis as indicated. C, in vitro ubiquitylation reaction
with purified recombinant MBP–TRIAD1, N8–CUL5–RBX2, His6-ubiquitin, and UBCH7 comparing DCNL1 and DCNL1(PONY) as substrates, including non-
UBCH7 control. Reaction products were separated on SDS-PAGE and detected by Coomassie stain as well as immunoblot analysis as indicated. D, purified
recombinant TRIAD1, N8–CUL5–RBX2, UBCH7, with eithermock, HA-ubiquitin (WT), ormutant HA-ubiquitin (I44A) andwith either DCNL1 or DCNL1 (PONY) as
substrates were subjected to an ubiquitylation reaction. Reaction products were separated on reducing SDS-PAGE followed by anti-HA immunoblot analysis.
Equal input of DCNL1 and DCNL1 (PONY) was verified by Coomassie-stained SDS-PAGE. Monoubiquitylated DCNL1 and DCNL1 (PONY) are indicated by * and
#, respectively. E, E3-free DCNL1 ubiquitylation reaction with either UBCH5c or UBCH7, including E2 drop-out control. Reaction products were separated on
SDS-PAGE followed by anti-HA immunoblot analysis or Coomassie staining to verify the presence of DCNL1. F and G, composition of ubiquitylation reactions
as in D, but the reaction was split into two steps. F, TRIAD1 was either mock or autoubiquitylated with HA-ubiquitin (HA-UbWT) before addition of DCNL1. G,
TRIAD1 was autoubiquitylated with either HA-ubiquitin (HA-UbWT) or mutant HA-ubiquitin (HA-UbI44A) before addition of DCNL1.
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Figure 5. DCNL1 activity is independent of its UBA domain and not altered by monoubiquitylation. Reconstitution of CUL5–RBX2 neddylation with
recombinant purified NEDD8-E1, N-terminally acetylated UBE2F, and WT DCNL1 or DCNL1 variants. Side-by-side comparisons of CUL5 neddylation in the
absence of DCNL1 (mock) and between DCNL1 and DAD-patchmutant of DCNL1 (A), and DCNL1 (PONY) (B), monoubiquitylated DCNL1-Ub (C), and ubiquitin
C-terminally-fused DCNL1-UbCT (D) are shown. CUL5 neddylation was monitored by silver-stained SDS-PAGE and immunoblot analysis with anti-CUL5 anti-
body. Ratio of N8-CUL5 (in %) was determined from silver-stained SDS-PAGE using ImageJ software. Standard error of the mean is given from at least two
independent replications.
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monoubiquitylation and thereby impacts someCRL assemblies
and activities.
Initially, we showed that monoubiquitylated DCNL1 is part
of CRL complexes and that the monoubiquitylated form of
DCNL1 is strongly reduced in cells expressing E3 ligase-inac-
tive TRIAD1 and HHARI, suggesting that both Ariadne RBR
ligases are required to ligate a single ubiquitin molecule onto
DCNL1. We were able to reconstitute DCNL1 monoubiquity-
lation in vitro with recombinant purified proteins (Figs. 2 and
4), which allowed us to further dissect the mechanism and
molecular determents. 1) DCNL1monoubiquitylation depends
on DCNL1’s conserved N-terminal UBA domain. Despite the
presence of several lysine residues as potential ubiquitylation
sites (Fig. S2), the UBA-truncated form of DCNL1 is only a very
poor substrate of N8–CUL5–RBX2-activated TRIAD1. These
in vitro data are supported by the observation thatUBA-deleted
DCNL1 expressed in cells did not show any detectable monou-
biquitylation. 2) DCNL1 monoubiquitylation is mediated by a
noncovalent ubiquitin/UBA interaction. Ubiquitin’s Ile-44
hydrophobic patch is required for UBA interactions. Hence,
replacing WT ubiquitin with UBA binding–deficient ubiqui-
tin (I44A) in ubiquitylation reactions completely abolished
DCNL1 monoubiquitylation. 3) Autoubiquitylated TRIAD1
enhances DCNL1 monoubiquitylation by mediating the ubiq-
uitin/UBA interaction with DCNL1. 4) DCNL1 is strictly
monoubiquitylated, but this modification is not limited to a
specific lysine residue. Indeed, we identified several lysine res-
idues that were ubiquitylated in vitro (Fig. S2), and they
matched with ubiquitylation sites described in cellular ubiqui-
tinomedata sets (16, 43). Cumulatively, the described data fit all
the key features required of an E3-dependent coupled monou-
biquitylation. Such a mechanism was initially shown for the
HECT-type E3 ligase Nedd4L and the ubiquitin receptor Eps15
and was proposed for other UBD-containing proteins such as
Sts2 and Hrs (35, 36). In the case for Nedd4L, once Nedd4L is
autoubiquitylated, it can bind the ubiquitin interaction motif
(UIM) of Eps15 and promote monoubiquitylation. Alterna-
tively, theRBR-family E3 ligase Parkinwas shown to interact via
its UBL domain with the UIM of Eps15. In agreement with a
coupled monoubiquitylation mechanism, this UBL/UIM inter-
action was required to mediate Eps15 monoubiquitylation by
Parkin. Whereas Nedd4L needs autoubiquitylation to establish
binding to UBA, Parkin uses an intrinsic UBL domain, suggest-
ing that there are alternative ways by which E3 ligases can pro-
vide a “ubiquitin adapter” to established the ubiquitin/UBA
interaction. Hence, both HECT- as well as RBR-type E3 ligases
can promote coupled monoubiquitylation reactions, which is
further supported by our finding that Ariadne RBRs are able to
monoubiquitylate ubiquitin receptors. Notably, it was reported
that Nedd4L can ubiquitylate DCNL1 in vitro; however, a
mechanism by coupled monoubiquitylation was not further
investigated (16). We recently described that HHARI is bound
to and activated by several CRL complexes and is very efficient
in priming CRL client substrates with a single ubiquitin moiety
(30). In agreementwith this finding, TRIAD1 andHHARI ligase
activity seems to favor a single ubiquitin transfer to DCNL1. A
further restricting factor for DCNL1’s monoubiquitylation
might be theUBAdomain itself, if, for example, monoubiquitin
binds theUBAdomain in cis (or in the case ofDCNL1dimeriza-
tion in trans) and prevents further interaction between the
UBA domain and autoubiquitylated TRIAD1 or HHARI.
All members of the DCNL family share the PONY domain
with the conserved DAD patch, which is required for cullin
binding and neddylation in vitro and in vivo, but vary at their N
termini (14). In contrast, the functionality of these unique N
termini is less well understood, but recent investigations sug-
gest that N termini govern subcellular localization properties
and are post-translationally modified. For instance, DCNL3
was shown to be localized to the plasma membrane, which
depends on a lipid modification of its N-terminal domain (44).
N termini of DCNL4 variants and DCNL5 contain nuclear
localization sequences (14), and a Ser-41 at the N terminus of
DCNL5 is phosphorylated in response to Toll-like receptor sig-
naling (45). DCNL1 and DCNL2 possess an N-terminal UBA
domain that is not required for cullin binding and neddylation.
However, here we provide several lines of evidence that a func-
tional UBA is strictly required for coupled monoubiquitylation
of DCNL1. Interestingly, deletion of the UBA domain or mim-
icking constitutive monoubiquitylation by fusing ubiquitin to
the C terminus of DCNL1 (DCNL1-UbCT) impacts CRL func-
tion in an identical way. Both mutant versions change the
dynamic monoubiquitylation of DCNL1 and act as dominant-
negative proteins that disrupt the modulation of CRL complex
composition, as indicated by decreased abundance of CSN and
increased CAND1 binding in CRLs. The potential alteration in
deneddylation and in CAND1-mediated SR exchange might
decrease CRL activity, leading to the accumulation of CRL sub-
strates, as we have shown for HIF1 and IB (Fig. 6). The
defects are modest, as might be expected: cells deficient for
DCNL1 display little change in the steady-state neddylation
pattern of cullins (14, 15). Hence, there is a certain degree of
redundancy among DCNL family members, and this is likely to
be especially true for the UBA domain–containing members
DCNL1 and DCNL2. An alternative regulatory function of
UBAhas been proposed in a recent study suggesting that, under
conditions of proteasome inhibition, UBA-binding to polyu-
biquitin chains inhibits DCNL1’s neddylation activity, and it
subsequently decreases CRL-promoted ubiquitylation (31).
Overall, the biological importance of the UBA domain is high-
lighted by the finding that DCNL1 is frequently amplified
Figure 6. Monoubiquitylated DCNL1modulates CRL complex composition. A–C, immunoblot analysis of anti-HA-IP and cell lysates (INPUT) from HEK293
cells expressingmock, HA–DCNL1, HA–DCNL1 (PONY), or HA–DCNL1-UbCT was used tomonitor co-precipitated cullins (A), CSN subunits (B), as well as CAND1
and CRL substrate receptors (C). D, HEK293 cells expressing HA–DCNL1 or HA–DCNL1-UbCT were either mock-treated or pretreated with MG132 or MLN4924
as indicated, and cell lysates were assessed for Hif1 expression by immunoblot analysis. E, quantitation of Hif1 shown inD using ImageJ software. Standard
error of the mean is given from three independent experiments. t tests have been performed for indicated data sets. *, p  0.05 statistically significant. F,
HEK293 cells expressing HA–DCNL1 or HA–DCNL1-UbCT were stimulated with TNF for indicated times, and cell lysates were prepared and analyzed for the
expression of IB and phospho-Ser-536–p65 (P-p65) by immunoblotting. G, quantitation of IB shown in F using ImageJ software. Standard error of the
mean is given from three independent experiments. t tests have been performed for indicated data sets. *, p 0.05 statistically significant.
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and/or mutated in various tumors, including lung and squa-
mous cell carcinomas (hence DCNL1’s alternative name squa-
mous cell carcinoma-related oncogene, SCCRO) (31, 46, 47).
Interestingly, some mutations cluster within the UBA domain,
and these mutations abolish ubiquitin binding (Fig. 3B) (31).
Future studies will determine whether a defect in coupled
DCNL1monoubiquitylation promotes cancer cell proliferation
and whether it is the underlying mechanism that drives carci-
nogenesis. DCNL1’s implication in cancer has initiated numer-
ous efforts to explore it as a cancer drug target. Recent studies
described the isolation and development of small compounds
that inhibit DCNL1 function by blocking interaction with
acetylated UBE2M and its potency in killing certain types of
cancer (48, 49). Taken together we provide here a deeper func-
tional insight into DCNL1 as a critical player in CRL biology
and envision that this work will widen the scope for exploring
DCNL1 as a drug target.
Experimental procedures
Cell culture, cell lines, and transfection
Stably transfected human embryonic kidney (HEK293) cells
were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine,
antibiotics (100 units/ml penicillin, 0.1 mg/ml streptomycin),
and in the presence of selection with 100 g/ml hygromycin
and 15 g/ml blasticidin. Stable HA-tagged CUL5 cells and
GFP-tagged TRIAD1 and HHARI cells were described previ-
ously (28). All HA-tagged DCNL1 expression vectors were sta-
bly transfected into HEK293 using Invitrogen’s Flp-In T-Rex
system according to the manufacturer’s instructions. The
HA–DCNL1 and HA–DCNL1 (DADMUT) cells have been
described before in Scott et al. (48). Protein expression was
typically induced overnight using 1 g/ml tetracycline unless
indicated otherwise. Where indicated, cells were treated with
MLN4924 (Active Biochem) at a final concentration of 3 M
overnight and 2 or 20 M MG132 (InvivoGen) overnight.
Plasmids, vectors
All plasmids and vectors were purchased from MRC PPU
Reagents and Services.
Protein expression and purification
NEDD8, TRIAD1, UBCH7, UBCH5a, APPBP1–UBA3,
UBE2F, CUL5–RBX2, and HHARI were purified as described
previously (28). GST–USP2b andGST–NEDP1were expressed
in BL21 Escherichia coli cells and purified on GSH-Sepharose.
His6-DCNL1 variants and His6-ubiquitinM-2C (ubiquitin mod-
ified by inclusion of a nonnative cysteine at the N terminus)
were expressed in E. coli and purified by Ni2-Sepharose chro-
matography (the His6 tag was subsequently removed from
ubiquitinM-2C using tobacco etch virus protease). 5-Iodoacet-
amidofluorescein (5-IAF, ThermoFisher Scientific)–labeled
ubiquitin was generated by incubating 250Mpurified ubiquit-
inM-2Cwith a 10-foldmolar excess of 5-IAF in a buffer contain-
ing 50 mM Tris-HCl, pH 7.5, and 0.5 mM tris(2-carboxyethyl)-
phosphine for 4 h at 22 °C in the dark. Nonreacted 5-IAF was
removed by dialysis. Halo-DCNL1 and UBA-mutated Halo-
DCNL1 (F15A, M16A, F44A, and F45A) were expressed in
E. coli as GST–Halo fusion proteins. GSTwas removed using
C3 proteases, and Halo-tagged DCNL1 was coupled to
HaloLink resin (Promega).
To obtain pure recombinantmonoubiquitylated DCNL1, we
modified an in vitro ubiquitylation protocol previously
described for proliferating cell nuclear antigen monoubiquity-
lation (50). Ubiquitylation reaction containing 80 nM E1, 32M
UBCH5c (S22R) (a gift fromHelenWalden, University of Glas-
gow), 32 M HA-ubiquitin (UbHA), and 16 M His6-DCNL1 in
reaction buffer (25 mM Tris-HCl, pH 9.0, 50 mM NaCl, 3 mM
MgCl2, 2.5 mM ATP, and 0.1 mM DTT) was incubated at 37 °C
overnight. The ubiquitylation reaction was diluted 1:10 with
1 PBS supplemented with 10 mM imidazole and incubated
with 25 l of nickel-nitrilotriacetic acid–agarose (Qiagen) at
4 °C for 1.5 h. Beads were washed three times with PBS
(adjusted to 1MNaCl and 20mM imidazole) and twicewith PBS
(supplemented with 20 mM imidazole), and His6-DCNL1/
DCNL1-UbHA eluted with 400mM imidazole in PBS. To subse-
quently isolate His6-DCNL1-UbHA, the eluate was diluted in
HA-binding buffer (25 mMTris-HCl, pH 7.4, 500 nMNaCl, and
0.1% Triton X-100) and incubated with 50 l anti-HA affinity
gel (Sigma) at 4 °C for 2 h. Beads were washed withHA-binding
buffer, and His6-DCNL1-UbHA was eluted with 0.2 mg/ml HA
peptide (Sigma) in neddylation reaction buffer (50 mMHEPES-
NaOH, pH 7.4, 50 mM NaCl, 5 mM MgCl2, 5% glycerol, 0.2 mM
EDTA, and 0.02% Triton X-100) at 4 °C for 0.5 h.
Protein concentrations were determined by Bradford or
Micro BCATM protein assay kit (ThermoFisher Scientific)
according to manufacturer’s protocols, and proteins were ali-
quoted, flash-frozen, and stored at80 °C.
Ubiquitylation assays
TRIAD1-catalyzed ubiquitylation reactions were performed
as described previously (28). Quantitative analyses of DCNL1
monoubiquitylation were performed using 5-IAF–labeled
ubiquitin to allow the quantitative measurement of fluores-
cence incorporation during in vitro reactions. These reactions
contained 66 nM E1, 366 nM UbcH7, 1 M 5-IAF-Ub, 150 nM
TRIAD1, 78 nM neddylated CUL5–RBX2 complex, and varying
concentrations of DCNL1 (between 1 and 10 M) in a PBS
buffer containing 5 mM Mg2-ATP. 12-l aliquots were
removed at various time points from a 80-l reaction volume,
stopped by the addition of SDS sample buffer, and analyzed by
gel electrophoresis. Gels were imaged using a FLA-5100 fluo-
rescent image analyzer (FujiFilm) to visualize 5-IAF–labeled
ubiquitin. ImageJ software was used to quantify fluorescent gel
bands corresponding tomonoubiquitylatedDCNL1 and by ref-
erence to 5-IAF–labeled ubiquitin standards.
Ubiquitylation reactionwithHHARIwas carried out inReac-
tion Buffer (25 mM Tris-HCl, pH 7.6, 2.5 mM MgCl, 2.2 mM
ATP, and 20 mM NaCl) with 150 nM E1, 500 nM UBCH7 (or
UBCH5c as indicated), 20 M HA-Ub (Boston Biochem), 400
nM HHARIARI (29), and 2 M DCNL1 at 37 °C for 60 min.
Reactions were stopped by adding reducing SDS sample buffer
and boiled for 5 min. Reaction products were analyzed by
immunoblotting.
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DCNL1 ubiquitylation reactions with ubiquitylated
TRIAD1, as described in Fig. 4, F andG, were carried out in two
steps. In the first step, 0.33g of TRIADwas autoubiquitylated
in 30l of PBS reaction buffer with 150 nM E1, 500 nMUBCH7,
20MHA-Ub (or Ub-I44A as indicated), and 5mMMg2-ATP
at 37 °C for 30 min. A mock reaction was carried out in the
absence of ATP. In the second step, 2 M DCNL1, 20 M
HA-Ub, and 5mMMg2-ATPwere added, and the reactionwas
continued for further 15 and 30 min before immunoblot
analysis.
Neddylation assay with DCNL1
DCNL1 co-E3 ligase activity was assessed in an in vitro ned-
dylation assay with CUL5–RBX2 as substrates. Neddylation
reactions containing 100 nM of either DCNL1, DCNL1
(PONY), DCNL1-UbCT, or DCNL1 (DADMUT), 25 nM NAE1,
50 nM N-terminal acetylated UBE2F (gift from Brenda Schul-
man andDanny Scott), 14MNEDD8, and 80 nMCUL5–RBX2
in reaction buffer (50 M HEPES-NaOH, pH 7.4, 50 mM NaCl, 5
mM MgCl2, 5% glycerol, 0.2 mM EDTA, 0.02% Triton X-100,
and 5 mM Mg2-ATP) were incubated at 37 °C and stopped
after the indicated time points (0, 2, 5, and 10 min) by adding
4 SDS sample buffer complemented with DTT. 80% of the
reaction was separated on 4–12% BisTris SDS-polyacrylamide
gel (Invitrogen) for silver staining and 20% was analyzed by
immunoblotting using anti-CUL5 antibody. Silver stained gels
were scanned, NEDD8–CUL5 and CUL5 bands quantified
using ImageJ software.
In vitro assays to assess binding of DCNL1with ubiquitin,
ubiquitin chains, and ubiquitylated TRIAD1
His6-DCNL1 binding to ubiquitin-agarose and NEDD8-aga-
rose was carried out as described elsewhere (11). DCNL1 bind-
ing to tetra-ubiquitin chains of different linkage types was per-
formed as described (37). Briefly, 21 nmol of Halo-tagged WT
and UBA domain-mutated DCNL1 was coupled to 200 l of
HaloLink resin (Promega) in 1 ml of binding buffer (50 mM
Tris-HCl, pH 7.5, 0.05%Nonidet P-40, 1mMDTT) overnight at
4 °C. 10l of the Halo-DCNL1 resins were incubated with 1g
of tetra-ubiquitin chains (Met-1, Lys-6, Lys-11, Lys-29, Lys-33,
Lys-48, and Lys-63; tetra-ubiquitin synthesis and purifications
described in Ref. 37) in 500 l of binding buffer (50 mM Tris-
HCl, pH 7.5, 150mMNaCl, 0.1%Nonidet P-40, 5 mMDTT, and
0.5 mg/ml BSA) at 4 °C. Beads were extensively washed with
wash buffer (50mMTris-HCl, pH 7.5, 250mMNaCl, 0.2%Non-
idet P-40, 5 mMDTT). Precipitated tetra-ubiquitin chains were
separated on 4–12% BisTris SDS-polyacrylamide gel (Invitro-
gen) and detected by silver staining.
In vitro binding studieswith autoubiquitylatedTRIAD1were
carried out as follows: 10g ofMBP-tagged TRIAD1was ubiq-
uitylated in Reaction Buffer (50 M Tris-HCl, pH 9, 6 mM MgCl,
2.2 mM ATP, 0.1 mM DTT, and 50 mM NaCl) with 150 nM E1,
500 nM UBCH5c, and 20 M Ub at 37 °C for 120 min. Ubiqui-
tylated and untreated MBP–TRIAD1 was captured with amy-
lose resin (New England Biolabs). TRIAD1 coupled beads were
incubated with 2 M recombinant DCNL1 variants in binding
buffer (50 mM Tris-HCl, pH 8.0, 10 M ZnCl2, 250 mM NaCl,
10% glycerol, 0.5% Nonidet P-40, 2.5 mM 2-mercaptoethanol)
for 2 h at 4 °C. Beads were washed three times with binding
buffer, and precipitates were analyzed by immunoblot.
Treatment of HA–DCNL1, GFP–TRIAD1, and GFP–HHARI with
USP2 and NEDP1
HA–DCNL1-expressing cells were lysed in the presence of 5
mM 1,10-phenanthroline. 20 l of anti-HA resin (Sigma) was
incubatedwith 3mg of cell lysate for 2 h at 4 °C. The beads were
washed four times and then resuspended in 30 l of 50 mM
HEPES, pH 7.5, 100 mM NaCl, 2 mM DTT, 1 mM MgCl2, 0.01%
Brij-35. GST–USP2 or GST–NEDP1 was added to a final con-
centration of 1 M. Heat-inactivated GST–USP2 and GST–
NEDP1 were used as control (heated for 15 min at 100 °C).
Reactions were incubated at 30 °C for 1 hwith shaking and then
resuspended to a final volume of 100l in reducing SDS sample
loading buffer and analyzed by immunoblotting with anti-HA
antibody. For theDUB treatment of autoubiquitylated TRIAD1
and HHARI-, GFP–TRIAD1,- GFP–TRIAD1 (C310S)-, GFP–
HHARI-, and GFP–HHARI (C357S)-expressing cells were
extracted with lysis buffer (40 mM HEPES, pH 7.4, 120 mM
NaCl, 1% Triton X-100, 1 mM EDTA, and 5 mM 1,10-phenan-
throline (Sigma)), and GFP-tagged proteins isolated by immu-
noprecipitation using GFP–Trap-agarose beads (Chromotek).
GFP-trapped proteins were washed with lysis buffer and twice
with wash buffer (50 mM HEPES, pH 7.5, 100 mM NaCl, 2 mM
DTT, 1mMMgCl2, 0.01% Brij-35). USP2 treatment was carried
out as described for HA–DCNL1.
Preparation of cell extracts, subcellular fractionation, and
immunological techniques
Whole-cell extracts were prepared by incubating cells with
lysis buffer (40 mM HEPES, pH 7.4, 120 mM NaCl, 1% Triton
X-100, 1 mM EDTA, and 5 mM 1,10-phenanthroline (Sigma))
for 10 min on ice followed by mechanical disruption by pass-
ing through a 21-gauge needle. Lysates were clarified by
centrifugation.
To subfractionate cells, they were first lysed by mechanical
disruption in hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10mMKCl, 0.5mMDTT, “Complete” protease inhibitor
mixture (Roche Applied Science)) using a Dounce homoge-
nizer. Nuclei were collected by centrifugation (230 g, 5 min),
and the supernatants (consisting of the cytosolic fraction) were
further cleared by centrifugation (16,000  g, 15 min). Nuclei
were resuspended in a low-sucrose buffer (250 mM sucrose, 10
mMMgCl2, “Complete” protease inhibitormixture) and layered
over an equal volume of a high-sucrose buffer (880mM sucrose,
0.5 mM MgCl2, “Complete” protease inhibitor mixture) before
centrifugation at 2800  g for 10 min. The resulting nuclear
pellets were resuspended in a high-salt buffer (15mMTris-HCl,
pH 7.4, 1 mM EDTA, 500 mMNaCl, 1 mMMgCl2, 10% glycerol,
10mM 2-mercaptoethanol, “Complete” protease inhibitormix-
ture) and incubated on ice for 30 min to extract nuclear pro-
teins. Salt-extracted pellets were collected by centrifugation
(16,000 g, 30min), and the supernatant was retained (nuclear
salt extract). Pellets were washed twice with nuclease reaction
buffer (20 mM Tris-HCl, pH 7.4, 100 mM KCl, 2 mM MgCl2, 1
mM CaCl2, 300 mM sucrose, 0.1% Triton X-100, “Complete”
protease inhibitor mixture) and treated with 3 units/l micro-
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coccal nuclease (ThermoFisher Scientific) for 20 min at room
temperature in the same buffer. Samples were centrifuged at
2500  g for 5 min, and the supernatant was recovered (chro-
matin-bound fraction). Immunoprecipitations, pulldowns, and
immunoblots were performed as described elsewhere (28).
For quantitation described in Fig. 6, E and G, immunoblots
from at least three biological repetitions were scanned with an
Amersham Biosciences Imager 600 (GE Healthcare) and ana-
lyzed using ImageJ software.
Antibodies
The following primary antibodies were used for Western
blotting: anti-GFP (RocheApplied Science,monoclonal and in-
house polyclonal antibody raised against GFP(2–238)); anti-
ubiquitin FK2 (Enzo) and anti-HA tag (Cell Signaling and
Bethyl Laboratories); anti-His tag (Cell Signaling); anti-DCNL1
clone 3D7 (Sigma); anti--actin (Cell Signaling); anti-CUL1
(Invitrogen); anti-CUL2 (Invitrogen); anti-CUL4B (Sigma);
anti-Elongin-C (BioLegend); anti-RBX1 (ThermoFisher Scien-
tific); anti-CAND1, anti-IB, and anti-phospho(S536)–p65
(Cell Signaling); anti-CSN5 (Abcam); anti-Hif1 (R&D Sys-
tems); anti-RBX2 (Abcam); anti-CSN3 (Bethyl Lab); anti-
CSN7B (Epitomics); anti-CSN8 (Abcam); and anti-histone
H2A (Abcam). Polyclonal antibodies against CUL3, CUL4A,
CUL5, HHARI, and TRIAD1 have been described previously
(28).
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